Trial Profile
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Danvatirsen (Primary)
- Indications Ascites; Gastrointestinal cancer; Ovarian cancer
- Focus Therapeutic Use
- 08 Apr 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Apr 2015 New trial record